ArticleCureus2026
Topical Application of Human Umbilical Cord-Derived Mesenchymal Stem Cell Exosomes for a Deep Second-Degree Scald Burn Wound: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of stem cell-derived exosomes in skin wound healing: mechanisms, prospects, and challenges.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional treatments for deep second-degree scald burns are frequently associated with prolonged healing times and hypertrophic scarring. Exosomes derived from mesenchymal stem cells represent a promising cell-free therapeutic strategy owing to their capacity to promote tissue regeneration. This report describes a 46-year-old woman with an unremarkable medical history who sustained a deep burn to her left thigh. The injury, classified as deep second-degree per American Burn Association (ABA) standards and involving 1% of the total body surface area (TBSA), significantly hindered her daily activities. Although not life-threatening, the localized pain and wound extent caused substantial functional impairment. Following one week of standard wound care without significant clinical improvement, a topical formulation containing human umbilical cord-derived mesenchymal stem cell exosomes (UC-MSC-Exos; ExoVia, BIONET Therapeutics Corp., Taipei, Taiwan) was applied once daily for nine consecutive days. Progressive granulation tissue formation and accelerated re-epithelialization were observed throughout the treatment period. Complete wound closure was achieved by day 18 post-injury, and the one-month follow-up demonstrated excellent skin quality with minimal scarring. No adverse reactions occurred during the treatment course. These preliminary findings suggest that topical application of UC-MSC-Exos could potentially serve as a well-tolerated adjunctive therapy associated with favorable healing for deep second-degree scald burns. Further investigation through larger, controlled clinical trials is warranted to validate these preliminary observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.